Biomarker test for patients with colorectal cancer
New test provides more opportunities for proper care
“Today, less than 1 per cent of the lymph node volume is studied under a microscope. And if tumour cells are found, it is not possible to determine whether or not they are aggressive”, says Lina Olsson.
Hiloprobe’s newly developed test using biomarkers will change that.
Every year, 1.4 million people around the world are affected by colorectal cancer. The treatment is surgery, but this does not guarantee that the patient is cured. The tumour may have spread and cause relapse. The main sign that the tumour has spread is the discovery of tumour cells in the lymph nodes. Today’s method of making such a discovery is limited, which causes some patients to relapse while others undergo painful and expensive follow-up treatments unnecessarily.
A combination of biomarkers provides answers
The team at Hiloprobe has developed a test called ColoNode, based on a unique combination of biomarkers. This molecular measuring technique provides objective and specific test results.
“The test offers new medical information and new opportunities to show which patients require further treatment after surgery, and which do not”, says Lina Olsson.
In addition to patients, the target group consists of pathologists, surgeons and oncologists.
“Our test can be performed by the pathologists’ regular laboratory staff, which could facilitate the work of pathologists, and save them time”, emphasises Lina Olsson.
Simple process prevents suffering
Being able to obtain precise knowledge about whether or not further treatment is needed through a simple process could prevent a lot of suffering and save a lot of money in healthcare.
“Missing the spread of tumour cells and overtreatment are both very costly.”
HiloProbe’s biomarker combination is validated on the basis of clinical material from approximately 200 patients.
“We are in the final stages of developing the product format – a 96-hole plate including reagents, adapted to healthcare processes and instruments. We will now be starting a clinical research study together with a number of hospitals in Sweden. We are also planning to CE mark the product, and launch an international clinical study further down the line”, says Lina Olsson.
Updated: 16 June 2017
Text: Jörgen Olsson